KR920000789A - 면역글로불린 부분을 갖는 융합 단백질, 이의 제조방법 및 용도 - Google Patents
면역글로불린 부분을 갖는 융합 단백질, 이의 제조방법 및 용도 Download PDFInfo
- Publication number
- KR920000789A KR920000789A KR1019910010844A KR910010844A KR920000789A KR 920000789 A KR920000789 A KR 920000789A KR 1019910010844 A KR1019910010844 A KR 1019910010844A KR 910010844 A KR910010844 A KR 910010844A KR 920000789 A KR920000789 A KR 920000789A
- Authority
- KR
- South Korea
- Prior art keywords
- fusion protein
- immunoglobulin
- protein
- fused
- cell
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims 26
- 102000037865 fusion proteins Human genes 0.000 title claims 26
- 108060003951 Immunoglobulin Proteins 0.000 title claims 22
- 102000018358 immunoglobulin Human genes 0.000 title claims 22
- 108010000499 Thromboplastin Proteins 0.000 claims description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims 16
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 8
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 108010075944 Erythropoietin Receptors Proteins 0.000 claims 1
- 102100036509 Erythropoietin receptor Human genes 0.000 claims 1
- 108010074860 Factor Xa Proteins 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 claims 1
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 claims 1
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 claims 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 102100030859 Tissue factor Human genes 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 트롬보플라스틴 cDNA를 클로닝하기 위해 사용되는 서열로 부터 유도된 2개의 올리고뉴클레오타이드프로브 분자를 나타낸 것이다,
제2도는 트롬보플라스틴 아미노산 서열을 갖는 클론 2b-Apr의 전체 서열을 도시한 것이다.
Claims (22)
- 면역글로불린 계통군에 속하지 않는 인체 단백질 또는 이의 일부, 및 모든 아류의 면역글로불린 분자의 다양한 부분으로 구성된 가용성 융합단백질.
- 제1항에 있어서, 면역글로불린 부분이 인체 IgG중쇄의 불변부인 융합 단백질.
- 제2항에 있어서, 면역글로불린 부분이 인체 IgGl 중쇄의 불변부 또는 이의 단백질 A-결합 단편인 융합 단백질.
- 제2항 또는 3항에 있어서, 융합이 힌지 영역(hinge region)에서 발생하는 융합 단백질.
- 제1항 내지 4항중 어느 한 항에 있어서, 면역글로불린에 융합된 단백질이 막 단백질의 세포의 부분 또는 이의 일부인 융합 단백질.
- 제1항 내지 4항중 어느 한 항에 있어서, 면역글로불린에 융합된 단백질이 트롬보플라스틴의 세포의 부분 또는 이의 일부인 융합 단백질.
- 제1항 내지 4항중 어느 한 항에 있어서, 면역글로불린에 융합된 단백질이 시토킨(cytokine)수용체 또는 성장인자 수용체의 세포외 부분 또는 이들의 일부인 융합 단백질.
- 제7항에 있어서, 면역글로불린에 융합된 단백질이 IL-4 수용체의 세포의 부분 또는 이의 일부인 융합 단백질.
- 제7항에 있어서, 면역글로불린에 융합된 단백질이 IL-7 수용체의 세포의 부분 또는 이의 일부인 융합 단백질.
- 제7항에 있어서, 면역글로불린에 융합된 단백질이 종양괴사인자 수용체의 세포의 부분 또는 이의 일부인 융합 단백질.
- 제7항에 있어서, 면역글로불린에 융합된 단백질이 G-CSF 수용체의 세포의 부분 또는 이의 일부인 융합 단백질.
- 제7항에 있어서, 면역글로불린에 융합된 단백질이 GM-CSF 수용체의 세포의 부분 또는 이의 일부인 융합 단백질.
- 제7항에 있어서, 면역글로불린에 융합된 단백질이 에리트로포이에틴 수용체의 세포의 부분 또는 이의 일부인 융합 단백질.
- 제1항 내지 4항중 어느 한 항에 있어서, 면역글로불린에 융합된 단백질이 막-결합되지 않은 가용성단백질 또는 이의 일부인 융합 단백질.
- 제14항에 있어서, 면역글로불린에 융합된 단백질이 시토킨 또는 성장인자 또는 이들의 일부인 융합 단백질.
- 제15항에 있어서, 면역글로불린에 융합된 단백질이 에리트로포이에틴 또는 이의 일부인 융합 단백질.
- 제15항에 있어서, 면역글로불린에 융합된 단백질이 GM-CSF 또는 G-CSF 또는 이들의 일부인 융합단백질.
- 제15항에 있어서, 면역글로불린에 융합된 단백질이 인터루킨 IL-1 내지 IL-8또는 이의 일부인 융합단백질.
- 제1항 내지 18항중 어느 한 항에 있어서 인자 Xa절단 부위가 면역글로불린 부분과 비-면역글로불린 부분사이에 추가로 삽입되는 융합 단백질.
- 제1항 내지 19항중 어느 한 항에 있어서, 청구된 융합 단백질의 암호화 DNA 를 포유동물세포 발현 시스셈에 도입시키고 발현시킨 후 생성된 융합 단백질을 면역글로불린 부분을 경유한 친화도 크로마토그라피에 의해 정제함을 특징으로 하여, 제1항 내지 19항중 어느 한 항에 청구된 융합 단백질을 제조하는 방법.
- 진단을 위한 제1항 내지 19항중 어느 한 항에 청구된 융합 단백질의 용도.
- 치료를 위한 제1항 내지 19항중 어느 한 항에 청구된 융합 단백질의 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4020607.6 | 1990-06-28 | ||
| DE4020607 | 1990-06-28 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019990009326A Division KR100280070B1 (ko) | 1990-06-28 | 1999-03-19 | 면역글로불린 부분을 갖는 융합 단백질 및 이의 제조방법 |
| KR1019990009324A Division KR100280069B1 (ko) | 1990-06-28 | 1999-03-19 | 면역글로불린 부분을 갖는 융합 단백질, 이의 제조방법 및 이를포함하는 약제학적 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR920000789A true KR920000789A (ko) | 1992-01-29 |
| KR100249572B1 KR100249572B1 (ko) | 2000-03-15 |
Family
ID=6409260
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019910010844A KR100249572B1 (ko) | 1990-06-28 | 1991-06-28 | 면역글로불린 부분을 갖는 융합 단백질 및 이의 제조방법 |
| KR1019990009326A KR100280070B1 (ko) | 1990-06-28 | 1999-03-19 | 면역글로불린 부분을 갖는 융합 단백질 및 이의 제조방법 |
| KR1019990009324A KR100280069B1 (ko) | 1990-06-28 | 1999-03-19 | 면역글로불린 부분을 갖는 융합 단백질, 이의 제조방법 및 이를포함하는 약제학적 조성물 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019990009326A KR100280070B1 (ko) | 1990-06-28 | 1999-03-19 | 면역글로불린 부분을 갖는 융합 단백질 및 이의 제조방법 |
| KR1019990009324A KR100280069B1 (ko) | 1990-06-28 | 1999-03-19 | 면역글로불린 부분을 갖는 융합 단백질, 이의 제조방법 및 이를포함하는 약제학적 조성물 |
Country Status (17)
| Country | Link |
|---|---|
| EP (3) | EP0835939B8 (ko) |
| JP (2) | JPH05247094A (ko) |
| KR (3) | KR100249572B1 (ko) |
| AT (2) | ATE169030T1 (ko) |
| AU (1) | AU655421B2 (ko) |
| CA (1) | CA2045869C (ko) |
| CY (2) | CY2151B1 (ko) |
| DE (3) | DE10075010I2 (ko) |
| DK (2) | DK0464533T3 (ko) |
| ES (2) | ES2120949T4 (ko) |
| GR (1) | GR3027567T3 (ko) |
| HK (2) | HK1010216A1 (ko) |
| IE (1) | IE912256A1 (ko) |
| LU (1) | LU90592I2 (ko) |
| NL (1) | NL300009I2 (ko) |
| PT (1) | PT98113B (ko) |
| UY (1) | UY25897A1 (ko) |
Families Citing this family (145)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5395760A (en) * | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| US6541610B1 (en) | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
| NZ235148A (en) | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| EP0417563B1 (de) * | 1989-09-12 | 2000-07-05 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
| EP0533006A1 (en) * | 1991-09-18 | 1993-03-24 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Chimaeric interleukin 5-receptor/immunoglobulin polypeptides |
| DE4322330A1 (de) | 1992-08-31 | 1994-03-03 | Behringwerke Ag | Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen |
| US6274348B1 (en) | 1992-05-19 | 2001-08-14 | Xoma Corporation | Methods for the preparation of positively charged proteins |
| US5643570A (en) * | 1992-05-19 | 1997-07-01 | Xoma Corporation | BPI-immunoglobulin fusion proteins |
| DE4228839A1 (de) | 1992-08-29 | 1994-03-03 | Behringwerke Ag | Verfahren zum Nachweis und zur Bestimmung von Mediatoren |
| JPH08511682A (ja) * | 1993-04-30 | 1996-12-10 | インサイト ファーマシューティカルズ，インク． | 組み換えｂｐｉ蛋白およびｌｂｐ蛋白、それをコードする核酸分子、その生産方法並びにそれらの使用 |
| DE4407386B4 (de) * | 1994-03-05 | 2009-01-15 | Dade Behring Marburg Gmbh | Verfahren zur Reaktivierung von gereinigten Membranproteinen durch Einfrieren |
| EP0706658B1 (en) * | 1994-04-28 | 2001-06-27 | Dade Behring Inc. | Calibrator for prothrombin time (pt) assays |
| BR9508469A (pt) * | 1994-07-29 | 1997-09-16 | Smithkline Beecham Plc | Proteína solúvel tendo antagonista il4 e/ou il13 ou atividade antagonista parcial composto processo para a preparação do mesmo polímero de DNA vetor de exemplo replicável célula hospedeira composição farmacêutica processo para tratar condições e uso do composto |
| US6410008B1 (en) | 1994-12-12 | 2002-06-25 | Beth Israel Hospital Association | Chimeric IL-10 proteins and uses thereof |
| WO1996018412A1 (en) | 1994-12-12 | 1996-06-20 | Beth Israel Hospital Association | Chimeric cytokines and uses thereof |
| EP0805628B1 (en) * | 1995-01-17 | 2003-05-02 | Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| DE19538716A1 (de) * | 1995-10-18 | 1997-04-24 | Behringwerke Ag | Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa) |
| US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
| US7427492B1 (en) | 1995-06-05 | 2008-09-23 | Human Genome Sciences, Inc. | Polynucleotides encoding human tumor necrosis factor receptor-like2 |
| AU6163196A (en) * | 1995-06-07 | 1996-12-30 | Smithkline Beecham Corporation | Method for obtaining receptor agonist antibodies |
| GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
| DE19538715A1 (de) * | 1995-10-18 | 1997-04-30 | Behringwerke Ag | Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII |
| US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
| US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
| US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
| US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
| US5866341A (en) * | 1996-04-03 | 1999-02-02 | Chugai Pharmaceutical Co., Ltd. | Compositions and methods for screening drug libraries |
| KR20010102191A (ko) | 1996-08-16 | 2001-11-15 | 벤슨 로버트 에이치. | 인간의 엔도킨 알파 단백질 |
| PT963377E (pt) | 1996-08-30 | 2009-05-11 | Human Genome Sciences Inc | Interleucina 19 |
| AU731553B2 (en) | 1996-10-25 | 2001-04-05 | Human Genome Sciences, Inc. | Neutrokine alpha |
| ES2312179T3 (es) | 1996-12-06 | 2009-02-16 | Amgen Inc. | Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1. |
| US6455040B1 (en) | 1997-01-14 | 2002-09-24 | Human Genome Sciences, Inc. | Tumor necrosis factor receptor 5 |
| US8329179B2 (en) | 1997-01-28 | 2012-12-11 | Human Genome Sciences, Inc. | Death domain containing receptor 4 antibodies and methods |
| US6342363B1 (en) | 1997-01-28 | 2002-01-29 | Human Genome Sciences, Inc. | Death domain containing receptor 4 nucleic acids and methods |
| US6433147B1 (en) | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
| US7452538B2 (en) | 1997-01-28 | 2008-11-18 | Human Genome Sciences, Inc. | Death domain containing receptor 4 antibodies and methods |
| US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| CA2291221A1 (en) | 1997-05-30 | 1998-12-03 | Human Genome Sciences, Inc. | 32 human secreted proteins |
| US6242570B1 (en) | 1997-07-10 | 2001-06-05 | Beth Israel Deaconess Medical Center | Production and use of recombinant protein multimers with increased biological activity |
| AU8182298A (en) * | 1997-07-10 | 1999-02-08 | Beth Israel Deaconess Medical Center | Recombinant erythropoietin / immunoglobulin fusion proteins |
| US6187564B1 (en) | 1997-07-10 | 2001-02-13 | Beth Israel Deaconess Medical Center | DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics |
| US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| JP2002017353A (ja) * | 1997-12-19 | 2002-01-22 | Japan Tobacco Inc | 変性ｌｄｌの定量方法 |
| ES2245085T3 (es) | 1998-01-23 | 2005-12-16 | Immunex Corporation | Adn y polipeptidos acpl. |
| EP1982990A1 (en) | 1998-03-19 | 2008-10-22 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
| US6472179B2 (en) * | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7083949B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| EP1123401A1 (en) | 1998-10-22 | 2001-08-16 | The General Hospital Corporation | BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP) |
| DK1141237T3 (da) | 1998-12-31 | 2006-02-13 | Gen Hospital Corp | PTH-receptor og screeningsassay der anvender denne |
| AU3224700A (en) | 1999-02-08 | 2000-08-25 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
| CA2363779A1 (en) | 1999-02-26 | 2000-08-31 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
| AU766507B2 (en) * | 1999-05-07 | 2003-10-16 | Genentech Inc. | Novel chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
| US6362324B1 (en) | 1999-06-30 | 2002-03-26 | Millennium Pharmaceuticals, Inc. | 17867 a novel human aminopeptidase |
| US6369210B1 (en) | 1999-06-30 | 2002-04-09 | Millennium Pharmaceuticals, Inc. | 22012, human carboxypeptidase |
| WO2001023521A2 (en) | 1999-09-29 | 2001-04-05 | The General Hospital Corporation | Polypeptide derivatives of parathyroid hormone (pth) |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| US6248353B1 (en) | 1999-12-10 | 2001-06-19 | Dade Behring Inc. | Reconstitution of purified membrane proteins into preformed liposomes |
| US20030143226A1 (en) * | 2000-03-02 | 2003-07-31 | Yuko Kobayashi | Human monoclonal antibodies against oxidized ldl receptor and medicinal use thereof |
| EP1712239A3 (en) | 2000-05-12 | 2007-08-22 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
| EP2292665B1 (en) | 2000-05-26 | 2015-07-08 | Immunex Corporation | Use of interleukin-4 antibodies and compositions thereof |
| ATE497007T1 (de) | 2000-08-25 | 2011-02-15 | Basf Plant Science Gmbh | Polynukleotide, die für prenylproteasen aus pflanzen kodieren |
| US6989247B2 (en) | 2000-11-28 | 2006-01-24 | Celltech R & D, Inc. | Compositions and methods for diagnosing or treating psoriasis |
| EP1683865A3 (en) | 2001-02-02 | 2006-10-25 | Eli Lilly & Company | Mammalian proteins and in particular CD200 |
| CA2444632A1 (en) | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
| CA2446723C (en) | 2001-05-25 | 2014-01-21 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US7361341B2 (en) | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| RS54274B1 (en) | 2001-06-26 | 2016-02-29 | Amgen Fremont Inc. | Opgl antibodies |
| US7572765B2 (en) | 2001-07-23 | 2009-08-11 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (PTH) analogs |
| KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| AU2003254016A1 (en) | 2002-07-19 | 2004-02-09 | Catholic Healthcare West | Methods and compositions relating to chimeric nicotinic receptor subunits |
| CN1705679B (zh) | 2002-10-15 | 2011-04-06 | 英特塞尔股份公司 | 编码b族链球菌粘着因子的核酸、b族链球菌的粘着因子和它们的用途 |
| US7638136B2 (en) | 2003-03-04 | 2009-12-29 | Intercell Ag | Streptococcus pyogene antigens |
| EP1610813A4 (en) | 2003-03-19 | 2009-07-01 | Gen Hospital Corp | PARATHYROIDAL HORMONES CONFORMALLY CONFORMALLY CONSTRAINED WITH PROPELLER STABILIZERS $ G (A) |
| EP2336357A1 (en) | 2003-04-15 | 2011-06-22 | Intercell AG | S. pneumoniae antigens |
| AU2012203896B2 (en) * | 2003-05-06 | 2014-09-25 | Bioverativ Therapeutics Inc. | Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia |
| PT2298347E (pt) | 2003-05-06 | 2016-01-29 | Biogen Hemophilia Inc | Proteínas quiméricas de fator de coagulação para o tratamento de um disturbio hemostático |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| EP2289907A3 (en) | 2003-05-07 | 2011-08-31 | Intercell AG | Streptococcus agalactiae antigens I + II |
| WO2004106367A2 (en) | 2003-05-30 | 2004-12-09 | Intercell Ag | Enterococcus antigens |
| US7910544B2 (en) | 2003-07-17 | 2011-03-22 | The General Hospital Corporation | Conformationally constrained parthyroid hormone (PTH) analogs |
| US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
| EP1682581B1 (en) | 2003-11-13 | 2012-04-25 | Hanmi Holdings Co., Ltd | Igg fc fragment for a drug carrier and method for the preparation thereof |
| KR101161819B1 (ko) | 2004-04-22 | 2012-07-03 | 테일크리스 바이오쎄러퓨틱스 아이엔씨. | 재조합적으로 변형된 플라스민 |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| AU2005267062C1 (en) | 2004-07-22 | 2013-01-17 | Five Prime Therapeutics, Inc. | Compositions and methods of use for MGD-CSF in disease treatment |
| WO2006027346A2 (en) | 2004-09-06 | 2006-03-16 | Altana Pharma Ag | Novel pyrazolopyrimidines |
| AU2005313492B2 (en) * | 2004-12-09 | 2011-12-15 | Merck Patent Gmbh | IL-7 variants with reduced immunogenicity |
| NZ562221A (en) | 2005-04-07 | 2011-06-30 | Cleveland Clinic Foundation | Xenotropic murine leukemia virus related virus (XMRV) associated with cancer |
| KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물 |
| MY149128A (en) | 2005-08-16 | 2013-07-15 | Hanmi Science Co Ltd | A method for the mass production of immunoglobulin fc region deleted initial methionine residues |
| AU2006287315B2 (en) | 2005-09-09 | 2013-02-21 | The Johns Hopkins University | Manipulation of regulatory T cell and DC function by targeting neuritin gene using antibodies, agonists and antagonists |
| WO2007142667A2 (en) | 2005-10-13 | 2007-12-13 | Human Genome Sciences, Inc. | Treatment of patients with autoantibody positive disease |
| AU2006311661B2 (en) | 2005-11-07 | 2011-05-26 | The Scripps Research Institute | Compositions and methods for controlling tissue factor signaling specificity |
| EP1785434A1 (en) | 2005-11-11 | 2007-05-16 | Ludwig-Maximilians-Universität München | Targeting and tracing of antigens in living cells |
| CN101528921B (zh) | 2006-01-20 | 2013-11-20 | 细胞信号技术有限公司 | 人非小细胞肺癌中的易位和突变的ros激酶 |
| US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
| US8623639B2 (en) | 2006-04-20 | 2014-01-07 | Becton, Dickinson And Company | Thermostable proteins and methods of making and using thereof |
| US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| EP2054077A4 (en) | 2006-08-04 | 2010-10-13 | Gen Hospital Corp | POLYPEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) |
| EP2289906A1 (en) | 2006-09-15 | 2011-03-02 | Intercell AG | Borrelia antigens |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| KR100888022B1 (ko) | 2006-12-21 | 2009-03-09 | 재단법인 목암생명공학연구소 | 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8Ｆｃ |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| EP2338902A1 (en) | 2007-05-02 | 2011-06-29 | Intercell AG | Klebsiella antigens |
| EP2511291A3 (en) | 2007-06-18 | 2012-11-07 | Intercell AG | Chlamydia antigens |
| BRPI0814465B1 (pt) | 2007-07-26 | 2021-11-23 | Novagen Holding Corporation | Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica |
| JP5711966B2 (ja) | 2007-08-01 | 2015-05-07 | ザ ジェネラル ホスピタル コーポレイション | Ｇタンパク質共役受容体および関連組成物を使用するスクリーニング方法 |
| AU2008304896B9 (en) | 2007-09-27 | 2014-12-18 | Japan Tobacco Inc. | Factor involved in latent infection with herpesvirus, and use thereof |
| JP5769968B2 (ja) | 2007-10-18 | 2015-08-26 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト非小細胞肺癌における転座および変異ｒｏｓキナーゼ |
| EP2242769B1 (en) | 2008-01-11 | 2016-11-02 | Adheron Therapeutics, Inc. | Anti-cadherin-11 ec1 domain antibodies for treating inflammatory joint disorders |
| EP2274437B1 (en) | 2008-04-10 | 2015-12-23 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
| KR20160110544A (ko) | 2008-06-04 | 2016-09-21 | 그리폴스 테라퓨틱스 인코포레이티드 | 플라스민의 제조를 위한 조성물, 방법 및 키트 |
| CA2731546C (en) | 2008-07-23 | 2013-11-19 | Hanmi Holdings Co., Ltd. | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
| HUE035769T2 (en) | 2009-02-12 | 2018-05-28 | Cell Signaling Technology Inc | Mutant ROS expression in human liver cancer |
| EP2405938A2 (en) | 2009-02-13 | 2012-01-18 | Intercell AG | Nontypable haemophilus influenzae antigens |
| HUE025670T2 (en) | 2009-03-03 | 2016-04-28 | Grifols Therapeutics Inc | A method for producing plasminogen |
| TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| AU2011205402B2 (en) | 2010-01-15 | 2015-02-05 | Amgen K-A, Inc. | Antibody formulation and therapeutic regimens |
| WO2011090971A2 (en) | 2010-01-19 | 2011-07-28 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for male reproductive disorders |
| WO2013033680A1 (en) | 2011-09-02 | 2013-03-07 | Lifenet Health | Bmp peptides & methods of use |
| WO2011140173A1 (en) | 2010-05-04 | 2011-11-10 | The Brigham And Women's Hospital, Inc. | Detection and treatment of fibrosis |
| BR112012028949B1 (pt) | 2010-05-13 | 2020-11-17 | Chugai Seiyaku Kabushiki Kaisha | polipeptídeo análogo do hormônio paratireoideo, seu uso e método de produção, bem como ácido nucleico, vetor de expressão, célula e composição farmacêutica |
| MX343376B (es) | 2010-07-15 | 2016-11-03 | Adheron Therapeutics Inc | Anticuerpos humanizados que tienen como objetivo el dominio ec1 de cadherina-11 y composiciones y metodos relacionados. |
| US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| EP2855521A4 (en) | 2012-05-24 | 2016-03-02 | Mountgate Group Ltd | COMPOSITIONS AND METHODS ASSOCIATED WITH THE PREVENTION AND TREATMENT OF RABIC INFECTION |
| EP2685260A1 (en) | 2012-07-09 | 2014-01-15 | Ludwig-Maximilians-Universität München | Direct and quantitative detection of targets in living cells |
| KR101609840B1 (ko) * | 2012-07-12 | 2016-04-07 | 한국생명공학연구원 | 항체의 Ｆｃ 부위 결합 펩타이드를 이용한 항체 정제용 흡착 칼럼 |
| PE20200607A1 (es) | 2012-09-11 | 2020-03-10 | Coherus Biosciences Inc | Etanercept correctamente plegado de alta pureza y excelente rendimiento |
| KR102073748B1 (ko) | 2013-01-31 | 2020-02-05 | 한미약품 주식회사 | 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법 |
| WO2014152497A2 (en) | 2013-03-15 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for cognitive disorders |
| AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
| JP6596014B2 (ja) | 2014-03-31 | 2019-10-23 | アムジェン ケー・エー，インコーポレイテッド | 爪および頭皮乾癬の治療方法 |
| WO2016040488A2 (en) | 2014-09-10 | 2016-03-17 | Georgetown University | Compositions and methods of using interleukin-4 induced gene 1 (il4i1) |
| US11191811B2 (en) | 2014-11-19 | 2021-12-07 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for frailty associated with aging |
| KR20170138426A (ko) | 2015-03-13 | 2017-12-15 | 삼성바이오에피스 주식회사 | 항-tnf-알파 폴리펩티드 조성물 및 그 용도 |
| US11591385B2 (en) | 2017-11-09 | 2023-02-28 | Pinteon Therapeutics Inc. | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies |
| WO2019244107A1 (en) | 2018-06-21 | 2019-12-26 | Daiichi Sankyo Company, Limited | Compositions including cd3 antigen binding fragments and uses thereof |
| WO2020053808A1 (en) | 2018-09-12 | 2020-03-19 | Georg Dewald | Method of diagnosing vasoregulatory disorders |
| EP3938400A4 (en) | 2019-03-11 | 2022-11-23 | Memorial Sloan Kettering Cancer Center | Cd22 antibodies and methods of using the same |
| CN117425500A (zh) | 2021-01-13 | 2024-01-19 | 纪念斯隆凯特琳癌症中心 | 抗dll3抗体-药物缀合物 |
| CN117425501A (zh) | 2021-01-13 | 2024-01-19 | 纪念斯隆凯特琳癌症中心 | 抗体-吡咯并苯二氮䓬衍生物缀合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0269455A3 (en) * | 1986-11-28 | 1989-09-06 | Takeda Chemical Industries, Ltd. | Highly purified fused protein comprising human ige fc fragment and production thereof |
| PT89484B (pt) * | 1988-01-22 | 1994-03-31 | Gen Hospital Corp | Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao |
| JPH05500611A (ja) * | 1989-08-23 | 1993-02-12 | ザ・ジェネラル・ホスピタル・コーポレーション | 非ヒト霊長類ｃｄ４ポリペプチド、グリコシル化可能なヒトｃｄ４分子、その断片、その融合タンパク質、その遺伝子配列および使用 |
| US5395760A (en) * | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| EP0417563B1 (de) * | 1989-09-12 | 2000-07-05 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
| ES2178635T3 (es) * | 1990-11-09 | 2003-01-01 | Stephen D Gillies | Inmunoconjugados de citoquinas. |
| EP0533006A1 (en) * | 1991-09-18 | 1993-03-24 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Chimaeric interleukin 5-receptor/immunoglobulin polypeptides |
-
1991
- 1991-06-22 EP EP97120664A patent/EP0835939B8/de not_active Expired - Lifetime
- 1991-06-22 ES ES91110307T patent/ES2120949T4/es not_active Expired - Lifetime
- 1991-06-22 DE DE2000175010 patent/DE10075010I2/de active Active
- 1991-06-22 DE DE59109269T patent/DE59109269D1/de not_active Expired - Lifetime
- 1991-06-22 AT AT91110307T patent/ATE169030T1/de active
- 1991-06-22 EP EP91110307A patent/EP0464533B1/de not_active Expired - Lifetime
- 1991-06-22 DE DE59109032T patent/DE59109032D1/de not_active Expired - Lifetime
- 1991-06-22 EP EP05011561A patent/EP1586635A1/de not_active Withdrawn
- 1991-06-22 DK DK91110307T patent/DK0464533T3/da active
- 1991-06-22 AT AT97120664T patent/ATE309376T1/de not_active IP Right Cessation
- 1991-06-22 DK DK97120664T patent/DK0835939T3/da active
- 1991-06-22 ES ES97120664T patent/ES2251009T3/es not_active Expired - Lifetime
- 1991-06-27 CA CA002045869A patent/CA2045869C/en not_active Expired - Lifetime
- 1991-06-27 AU AU79357/91A patent/AU655421B2/en not_active Expired
- 1991-06-27 PT PT98113A patent/PT98113B/pt not_active IP Right Cessation
- 1991-06-27 IE IE225691A patent/IE912256A1/en not_active IP Right Cessation
- 1991-06-28 KR KR1019910010844A patent/KR100249572B1/ko not_active IP Right Cessation
- 1991-06-28 JP JP3183772A patent/JPH05247094A/ja active Pending
-
1998
- 1998-08-04 GR GR980401751T patent/GR3027567T3/el unknown
- 1998-10-14 HK HK98111254A patent/HK1010216A1/xx not_active IP Right Cessation
- 1998-12-11 HK HK98113232A patent/HK1012015A1/xx not_active IP Right Cessation
-
1999
- 1999-02-12 CY CY9900007A patent/CY2151B1/xx unknown
- 1999-03-19 KR KR1019990009326A patent/KR100280070B1/ko not_active IP Right Cessation
- 1999-03-19 KR KR1019990009324A patent/KR100280069B1/ko not_active IP Right Cessation
-
2000
- 2000-01-13 UY UY25897A patent/UY25897A1/es not_active Application Discontinuation
- 2000-05-31 LU LU90592C patent/LU90592I2/fr unknown
- 2000-06-09 NL NL300009C patent/NL300009I2/nl unknown
-
2001
- 2001-10-17 JP JP2001319607A patent/JP3768427B2/ja not_active Expired - Lifetime
-
2014
- 2014-06-18 CY CY2000009C patent/CY2000009I1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR920000789A (ko) | 면역글로불린 부분을 갖는 융합 단백질, 이의 제조방법 및 용도 | |
| EP0371998A4 (en) | Modular assembly of antibody genes, antibodies prepared thereby and use | |
| ATE92959T1 (de) | Herstellung von chimaeren antikoerpern. | |
| ATE279947T1 (de) | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten | |
| WO1993022332A3 (en) | Recombinant production of immunoglobulin-like domains in prokaryotic cells | |
| Bond et al. | A mouse T cell product that preferentially enhances IgA production. II. Physicochemical characterization. | |
| PL415463A1 (pl) | Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, fuzje polipeptydowe, komórki gospodarza, sposób wytwarzania fuzji polipeptydowych, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji, wyizolowana cząsteczka kwasu nukleinowego | |
| DE69433869D1 (de) | Alpha untereinheit des humanen beta-2 integrins | |
| EA005270B1 (ru) | СПОСОБ ВЫСОКОПРОДУКТИВНОЙ ЭКСПРЕССИИ АКТИВНЫХ ХИМЕРНЫХ БЕЛКОВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β И ИММУНОГЛОБУЛИНА И ИХ ВЫДЕЛЕНИЕ | |
| MX26714A (es) | Procedimiento para la preparacion de albumina de SUERO HUMANO VECTOR Y PLASMIDO USADOS ASI COMO LEVADURA METILOTROFICA TRANSFORMADA OBTENIDA | |
| DE3583634D1 (de) | Gentechnologisches verfahren zur herstellung von human-interleukin-2 und mittel zur durchfuehrung dieses verfahrens. | |
| Byrne et al. | Human granulocyte-macrophage colony-stimulating factor purified from a Hodgkin's tumor cell line | |
| DK0629238T3 (da) | Autotaxin:Motilitetsstimulerende protein, som er nyttigt til cancerdiagnose og terapi | |
| Pitti et al. | Molecular and biological properties of an interleukin-1 receptor immunoadhesin | |
| Reddy et al. | Reductive cleavage of the disulfide bonds of the collagen IV noncollagenous domain in aqueous sodium dodecyl sulfate: absence of intermolecular nondisulfide cross-links | |
| MIYATA et al. | Pruification of Natural Human Interferon-Gamma by Antibody Affinity Chromatography: Analysis of Constituent Protein Species in the Dimers | |
| DE3850933D1 (de) | Anticoagulatorisches Protein PP4-X, seine Herstellung und Verwendung. | |
| WO1987004466A1 (en) | Interleukin | |
| CA2218755A1 (en) | Monoclonal antibody to human beta 2 integrin alpha subunit | |
| EP0688224A4 (en) | MUTANT PROTEIN, METHODS AND MATERIALS USED FOR ITS MANUFACTURE AND USE | |
| JP3786433B2 (ja) | 均一なｎ末端を有する組換え型ヒトインターロイキン６及びその製造方法 | |
| KR890013177A (ko) | 신규폴리펩티드 및 그것을 코우드하는 dna | |
| ATE110112T1 (de) | Verfahren und systeme zur herstellung von hiv- antigenen. | |
| EP0603393A4 (en) | INTERLEUKIN 6 HUMAN RECOMBINATION WITH HOMOGENEOUS N TERMINATION AND PRODUCTION OF THIS INTERLEUKIN. | |
| JPH05508778A (ja) | リンホカイン１５４ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19910628 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| AMND | Amendment | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19960618 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19910628 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 19981020 Patent event code: PE09021S01D |
|
| A107 | Divisional application of patent | ||
| AMND | Amendment | ||
| PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 19990319 Patent event code: PA01071R01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 19990531 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 19981020 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| A107 | Divisional application of patent | ||
| J201 | Request for trial against refusal decision | ||
| PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 19990830 Patent event code: PA01071R01D |
|
| PJ0201 | Trial against decision of rejection |
Patent event date: 19990830 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 19990531 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 19991105 Appeal identifier: 1999101003181 Request date: 19990830 |
|
| PB0901 | Examination by re-examination before a trial |
Comment text: Request for Trial against Decision on Refusal Patent event date: 19990830 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 19990319 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 19960618 Patent event code: PB09011R02I |
|
| B701 | Decision to grant | ||
| PB0701 | Decision of registration after re-examination before a trial |
Patent event date: 19990929 Comment text: Decision to Grant Registration Patent event code: PB07012S01D Patent event date: 19990920 Comment text: Transfer of Trial File for Re-examination before a Trial Patent event code: PB07011S01I |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 19991227 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 19991228 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| G170 | Re-publication after modification of scope of protection [patent] | ||
| PG1701 | Publication of correction |
Patent event code: PG17011E01I Patent event date: 20000502 Comment text: Request for Publication of Correction Publication date: 20000701 |
|
| PR1001 | Payment of annual fee |
Payment date: 20021015 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20031030 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20041018 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20051031 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20061226 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20071224 Start annual number: 9 End annual number: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20081224 Start annual number: 10 End annual number: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20091224 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20101208 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20101208 Start annual number: 12 End annual number: 12 |
|
| EXPY | Expiration of term | ||
| PC1801 | Expiration of term |
Termination date: 20121009 Termination category: Expiration of duration |